The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total research and development expenses | 7,317 | - | - | - |
| Total general and administrative expenses | 4,119 | - | - | - |
| total other income (expense), net | 644 | - | - | - |
| Consolidated net loss | -10,792 | -13,964 | -25,746 | -34,413 |
| Depreciation and amortization | 162 | 166 | 165 | 333 |
| Stock-based compensation | 1,307 | 1,207 | 1,307 | 2,483 |
| Accretion of discount of available-for-sale investment securities | 255 | 361 | 512 | 981 |
| Amortization of right-of-use assets | 232 | 228 | 224 | 437 |
| Gain on disposal of property and equipment | - | 12 | - | - |
| Other receivables | -396 | -169 | 544 | -1,238 |
| Prepaid expenses and other assets | -91 | -1,094 | -4,795 | -1,445 |
| Accounts payable and accrued expenses | -3,467 | -536 | 18 | 485 |
| Operating lease liability | -191 | -187 | -183 | -341 |
| Net cash used in operating activities | -12,517 | -12,196 | -20,476 | -29,314 |
| Purchases of property and equipment | 138 | 31 | 37 | 9 |
| Purchases of available-for-sale investment securities | 5,868 | 12,845 | 39,340 | 41,260 |
| Maturities of available-for-sale investment securities | 17,500 | 29,307 | 19,000 | 40,150 |
| Proceeds from sale of property and equipment | - | 12 | - | - |
| Net cash provided by (used in) investing activities | 11,494 | 16,443 | -20,377 | -1,119 |
| Proceeds from issuance of common stock through option exercises | 0 | 0 | 0 | 19 |
| Proceeds from issuance of common stock through employee stock purchase plan | - | 29 | 0 | 79 |
| Proceeds from issuance of common stock from at-the-market offerings, net of offering costs | 0 | -21 | 29,753 | 36,691 |
| Proceeds from issuance of common stock from underwritten follow-on public offering, net of offering costs | - | 0 | - | - |
| Principal paid on finance lease liabilities | 142 | 139 | 136 | 264 |
| Net cash (used in) provided by financing activities | -142 | -131 | 29,617 | 36,525 |
| Net change in cash, cash equivalents and restricted cash | -1,165 | 4,116 | -11,236 | 6,092 |
| Cash, cash equivalents and restricted cash at beginning of period | 12,978 | 8,862 | 14,006 | - |
| Cash, cash equivalents and restricted cash at the end of period | 11,813 | 12,978 | 8,862 | - |
aTYR PHARMA INC (ATYR)
aTYR PHARMA INC (ATYR)